Last mentioned: Mar 17, 2026
Valuation Period
Expected timeframe for determining the fair market value of the equity investment.
Palliative Care Findings
New research confirms high efficacy rates for mitigating end-of-life distress in oncology settings.
Option Exercised
PsyLabs officially triggers the put option, requiring an equity investment from PBM.
Put Option Established
Psyence BioMed and PsyLabs enter into a strategic put option agreement.
SAP Expansion
Canada formally expands the Special Access Program to include restricted psychedelic substances.
Canadian Exemptions
Health Canada grants the first legal exemptions for psilocybin use to four terminally ill patients.
FDA Breakthrough Status
FDA grants Breakthrough Therapy designation to psilocybin for treatment-resistant depression.
Clinical research into psilocybin-assisted therapy is demonstrating significant potential in mitigating existential distress and depression among terminally ill patients. These findings are driving a re-evaluation of palliative care protocols and accelerating the push for expanded regulatory access to psychedelic-based treatments.
Psyence Biomedical Ltd. (Nasdaq: PBM) has confirmed a strategic equity investment in PsyLabs following the exercise of a previously established put option. This move deepens the integration between the biopharmaceutical developer and its primary manufacturer of pharmaceutical-grade psychedelic compounds.
This page surfaces every story mentioning Psilocybin across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Psilocybin was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |